Gifford Bioscience is a preclinical contract research organization (CRO) providing services in radioligand binding assays, receptor affinity and occupancy studies and autoradiography.
We are committed to delivering the best science. With this aim, we stick tightly to our core specialism and all of our researchers hold PhD’s.
We undertake standard or custom assays on our client’s samples to our client’s specification. In addition, our capabilities include assay design, cell culture, in-house production of membrane preparations and assays requiring human or animal tissue.
We are based at The BioHub Birmingham.
CONTACT US for a chat. We are always happy to discuss potential requirements and assay design.
“KD determination of drug binding to targets, by equilibrium and kinetic measurements, is an essential component of our mechanism of action analyses for drug development. Gifford Bioscience performs this service using radionuclides with the highest quality, in a cost effective and timely manner.”
Director of Biology, Californian Biotech, June 2019
The Management Team
Dr Andrew Gifford
Chairman and Chief Scientific Officer
Andrew was previously a Senior Scientist in the radiopharmaceutical development program at Brookhaven National Laboratory, New York. As a Principal Investigator, he has been responsible for the preclinical development of a variety of radiolabeled drugs. Techniques employed in his academic laboratories were primarily radiometric ligand binding and occupancy assays, radiolabeling chemistry and autoradiography.
Andrew is a graduate of Imperial College, London and was awarded his PhD in Pharmacology by the University of St. Andrews.
Mr Macer Gifford
Macer is a banker by profession. His 25 year career has spanned numerous senior roles. Most recently, he was Deputy Group CEO at Ahli United Bank. Macer was previously Group Head of Regional Markets at Standard Chartered PLC, where he spent 7 years as a Managing Director.
Macer is a graduate of the London School of Economics and a Sloan Fellow of the London Business School.
Dr Kevin Thompson
Kevin has 25-years Pharma, Biotech and CRO experience. He joined Gifford Bioscience in 2019 from a position as director of Screening and Operations at a UK Biotech. Kevin has considerable in vitro screening experience applied to diverse therapeutic targets. He applies his in-depth knowledge of binding kinetics to also oversee the SPR (Biacore) assay services. Kevin is a Biology graduate and was awarded his DPhil in Neurobiology, both at Sussex University.